Skip to main content
Livermore
Livermore
ZHEN

Cartesian Therapeutics, Inc.

RNAC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001453687

No open-market purchases or sales by Cartesian Therapeutics, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q2 2026, worth $90.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Cartesian Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Cartesian Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Cartesian Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Seven One Eight Three Four Irrevocable Trust10% Owner5,313,261IndirectApr 6, 20261
Hoge Elizabeth10% Owner5,313,261IndirectApr 6, 20261
Kalayoglu Murat10% Owner5,313,261IndirectApr 6, 20262
Singer MichaelDirector49,578Mar 13, 20263
Brunn CarstenPresident and CEO323,530Jan 8, 20262
Davis BlaineChief Financial Officer121,220Jan 8, 20262
Miljkovic MilosChief Medical Officer58,820Jan 8, 20262
Springer Timothy ADirector, 10% Owner8,646,285Jan 6, 20261
Zenner Patrick JDirector12,974Jan 6, 20261
Barabe Timothy CDirector56,966Jan 6, 20262
DeSilva Nishan MDirector11,366Jan 6, 20261
Malik KemalDirector11,133Jan 6, 20261
English EmilyChief Operations Officer94,226Jan 6, 20263
Seymour June AnnChief Accounting Officer6,500Jan 6, 20262
Bot Adrian IonDirector5,800Dec 18, 20251
Jewell Christopher MChief Scientific Officer62,490Jan 13, 20250
Kurtoglu MetinChief Technology Officer62,258Jan 7, 20250
Cox Carrie SmithDirector15,629Jan 6, 20250
Sallin AymericDirector178,000Jan 4, 20240
Myers Scott DunsethDirector–Nov 15, 20230
Traber Peter GChief Medical Officer451,826Sep 26, 20230
Kishimoto Takashi KeiChief Scientific Officer225,316Jun 1, 20230
Johnston Lloyd P.Chief Operations Officer265,515Jan 6, 20230
Ando GoranDirector–Jan 4, 20230
Tan KevinChief Financial Officer77,000Jan 5, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 13, 2021 (view filing)Dec 9-134 daysSpringer Timothy ADirector, 10% OwnerPPurchase+3.82M$3.06+$11.7M+19.9%23.0M after3 lots
Dec 6, 2021 (view filing)Dec 24 daysTan KevinChief Financial OfficerPPurchase+5.00K$3.03+$15.2KNew position5.00K after
Dec 6, 2021 (view filing)Dec 24 daysDeSilva Nishan MDirectorPPurchase+7.00K$2.96+$20.7KNew position7.00K after
Dec 6, 2021 (view filing)Dec 33 daysCox Carrie SmithDirectorPPurchase+17.2K$2.95+$50.7K+26.2%82.9K after
Dec 3, 2021 (view filing)Dec 21 dayBrunn CarstenPresident and CEOSSale−4.75K$2.96−$14.0K−1.6%285.0K after
Oct 15, 2021 (view filing)Oct 132 daysTraber Peter GChief Medical OfficerSSale−3.64K$4.39−$16.0K−2.3%154.7K after
Oct 15, 2021 (view filing)Oct 132 daysKishimoto Takashi KeiChief Scientific OfficerSSale−3.89K$4.39−$17.1K−2.0%190.4K after
Oct 15, 2021 (view filing)Oct 132 daysJohnston Lloyd P.Chief Operations OfficerSSale−3.89K$4.39−$17.1K−3.8%97.3K after
Oct 15, 2021 (view filing)Oct 132 daysBrunn CarstenPresident and CEOSSale−15.3K$4.39−$67.2K−5.2%278.8K after
Sep 3, 2021 (view filing)Sep 21 dayBrunn CarstenPresident and CEOSSale−4.52K$4.51−$20.4K−1.9%229.4K after
Aug 20, 2021 (view filing)Aug 182 daysBarabe Timothy CDirectorPPurchase+9.00K$4.00+$36.0K+5.0%190.0K after